` PAS (Pascal Biosciences Inc) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

PAS
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, PAS has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +29% growth.

Back to PAS Analysis

Stocks Performance
PAS vs S&P TSX Composite Index (Canada)

Loading
PAS
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
PAS vs S&P TSX Composite Index (Canada)

Loading
PAS
S&P TSX Composite Index (Canada)
Difference
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y

Performance By Year
PAS vs S&P TSX Composite Index (Canada)

Loading
PAS
S&P TSX Composite Index (Canada)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Pascal Biosciences Inc vs Peers

S&P TSX Composite Index (Canada)
PAS
ABBV
AMGN
GILD
VRTX
Add Stock
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Pascal Biosciences Inc
Glance View

Market Cap
983.9k CAD
Industry
Biotechnology

Pascal Biosciences, Inc. is a biotechnology company, which engages in developing breakthrough treatments in the field of immuno-oncology. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2012-03-16. The firm is engaged in the research and development of products for the treatment of cancers, and for improvement of the immune system. The firm operates in the segment of biotechnology research and development. The firm is focused on developing cannabinoid-based and targeted therapeutics to fight cancer. Its cannabinoid portfolio includes PAS-403, PAS-393 and Cannabinoid for corona virus disease-2019 (COVID-19). Its PAS-403 is a small molecule therapeutics for the treatment of glioblastoma. Its PAS-393, is an immune-stimulatory cannabinoid used in combination with checkpoint inhibitor therapy to treat multiple cancers. In addition, it is developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas.

PAS Intrinsic Value
Not Available
What is Intrinsic Value?
Back to Top
ALPHA SPREAD
Follow us
Join more than 304,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.